SUMMARY The cellular basis of trabecular bone loss in rheumatoid arthritis was investigated in 45 non-steroid treated patients. Mean wall thickness, an indicator of the amount of bone formed per remodelling unit, mean interstitial bone thickness, which is related to resorption depth, and the extent of trabecular surface covered by osteoid, which reflects the number of remodelling units, were assessed in iliac crest biopsy specimens. The mean wall thickness was significantly reduced in the patient group when compared with controls matched for age and sex (mean (SD) 39.8 (5.4) v 51-6 (9.7) ,tm). There was no significant difference between patients and controls in the mean interstitial bone thickness (51.0 (26.4) v 61.4 (31.9) fim) or osteoid surface (16-7 (11-4) 
An increased prevalence of generalised osteoporosis has been reported in patients with rheumatoid arthritis,1-though it is uncertain whether this is due to the disease itself or to related factors such as 3 4 
Results
The mean (SD) wall thickness in the whole group of patients was significantly lower than that in controls matched for age and sex (39.8 (5.4) v 51-6 (9.7) ,um, p<O-OOl). When patients were divided into men and women (Fig. 4) 
Discussion
Our results show a highly significant decrease in the amount of bone formed at trabecular remodelling sites in non-steroid treated patients with rheumatoid arthritis, and provide the first unequivocal histomorphometric evidence of reduced bone formation in these patients. These results are consistent with our earlier demonstration of trabecular thinning in the same group of patients'3 as bone loss due predominantly to reduced bone formation would tend to result in trabecular thinning, whereas bone loss associated with increased bone turnover with or without an increase in resorption depth would decrease the connectedness of trabecular bone with less effect on trabecular width. Our findings are also compatible with those reported by Ramser et al in rib cortical bone21; they showed reduced tetracycline uptake in three of five patients and reduced osteoid surface in four of seven patients with rheumatoid arthritis treated with salicylate. The increase in surface extent of resorption, which was found in all seven patients, may also have reflected decreased formation rather than increased resorption, previously resorbed cavities not being filled by new bone because of reduced bone formation. 28 Thus, depending on concurrent changes in mean wall thickness, a decreased mean interstitial bone thickness may be associated with a decreased, constant, or increased resorption depth, whereas a normal mean interstitial bone thickness could occur with either a constant or decreased resorption depth. Calculation of the resorption depth from mean trabecular width and mean wall thickness indicated, however, that resorption depth was close to normal in both male and female patients, thus excluding the possibility that increased resorption depth may also contribute to bone loss in rheumatoid arthritis. This finding is also consistent with our earlier demonstration of trabecular thinning in these patients'3 as increased resorption depth together with a reduction in mean wall thickness would rapidly lead to trabecular perforation with loss of connectedness.
In addition to reduced bone formation in individual remodelling units, which leads to irreversible bone loss, an increase in the activation of bone remodelling units along the trabecular surface may also result in trabecular bone loss, this being potentially reversible. Some estimate of whether the number of remodelling sites is increased or not can be obtained from measurement of the extent of the trabecular bone surface covered by resorption cavities or osteoid; as discussed earlier, however, the surface extent of resorption may be increased as a result of decreased bone formation rather than because of increased activation, so that the osteoid surface is probably a more reliable indicator. In this study the osteoid surface was within normal limits in all patients and the mean value did not differ significantly from that of the control group. Similar results have been reported in two other studies of iliac crest bone histomorphometry,"1 12 whereas osteoid surface was found to be reduced in rib cortical bone in the study of Ramser et al.2' Taken together, these studies thus indicate that the number of remodelling sites which are activated along the trabecular bone surface is not increased in rheumatoid arthritis and that decreased bone formation at the remodelling unit level therefore represents the main mechanism of bone loss in these patients.
The clinical significance of bone loss in rheumatoid arthritis has not been clearly established. There is some evidence that fracture rate is increased in patients treated with corticosteroids, but no such evidence exists for those not receiving steroids. 34 3 The role for routine prophylaxis against bone loss in these patients is therefore unclear; however, the demonstration that bone loss is predominantly due to reduced bone formation indicates that where treatment is required a drug which stimulates osteoblasts, such as sodium fluoride, may be most appropriate. 
